Single-nucleotide polymorphisms of GPX1 and MnSOD and susceptibility to bladder cancer: A systematic review and meta-analysis

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 759-764

  Cao, Ming ^a   Mu, Xin ^a   Jiang, Chen ^a   Yang, Guoliang ^a   Chen, Haige ^a   Xue, Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bladder cancer; GPX1; MnSOD; Polymorphism; Susceptibility

Indexed keywords

ALANINE; GLUTATHIONE PEROXIDASE 1; LEUCINE; MANGANESE SUPEROXIDE DISMUTASE; PROLINE; REACTIVE OXYGEN METABOLITE; VALINE;

ALLELE; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; GENETIC HETEROGENEITY; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; CASE-CONTROL STUDIES; CODON; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE PEROXIDASE; HUMANS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; SUPEROXIDE DISMUTASE; URINARY BLADDER NEOPLASMS;

EID: 84894505732     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1103-6     Document Type: Article

References (22)

1. Lamm DL, Griffith JG. Intravesical therapy: does it affect the natural history of superficial bladder cancer? Semin Urol. 1992;10(1):39-44.
2. Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev. 2000;9(5):461-7.
3. Zeegers MP, Kellen E, Buntinx F, van den Brandt PA. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol. 2004;21(6):392-401.
4. St Clair DK, Jordan JA, Wan XS, Gairola CG. Protective role of manganese superoxide dismutase against cigarette smoke-induced cytotoxicity. J Toxicol Environ Health. 1994;43(2):239-49.
5. Frederiks WM, Bosch KS, Hoeben KA, van Marle J, Langbein S. Renal cell carcinoma and oxidative stress: the lack of peroxisomes. Acta Histochem. 2010;112(4):364-71.
6. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. Histol Histopathol. 1997;12(2):525-35.
7. Wallace DC. Mitochondrial diseases in man and mouse. Science. 1999;283(5407):1482-8.
8. Arthur JR. The glutathione peroxidases. Cell Mol Life Sci. 2000;57(13-14):1825-35.
9. Kucukgergin C, Gokpinar M, Sanli O, Tefik T, Oktar T, Seckin S. Association between genetic variants in glutathione peroxidase 1 (GPx1) gene, GPx activity and the risk of prostate cancer. Minerva Urol Nefrol. 2011;63(3):183-90.
10. Kucukgergin C, Sanli O, Amasyali AS, Tefik T, Seckin S. Genetic variants ofMnSOD and GPX1 and susceptibility to bladder cancer in a Turkish population. Med Oncol. 2012;29(3):1928-34.
11. Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, et al. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis. 2004;25(6):973-8.
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100.
13. Goerlitz D, El Daly M, Abdel-Hamid M, Saleh DA, Goldman L, El Kafrawy S, et al. GSTM1, GSTT1 null variants, and GPX1 single nucleotide polymorphism are not associated with bladder cancer risk in Egypt. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1552-4.
14. Paz-y-Miño C, Munoz MJ, Lopez-Cortes A, Cabrera A, Palacios A, Castro B, et al. Frequency of polymorphisms pro198leu in GPX-1 gene and ile58thr in MnSOD gene in the altitude Ecuadorian population with bladder cancer. Oncol Res. 2010;18(8):395-400.
15. Ichimura Y, Habuchi T, Tsuchiya N,Wang L, Oyama C, Sato K, et al. Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J Urol. 2004;172(2):728-32.
16. Vineis P, Veglia F, Garte S, Malaveille C, Matullo G, Dunning A, et al. Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol. 2007;18(7):1230-42.
17. Cengiz M, Ozaydin A, Ozkilic AC, Dedekarginoglu G. The investigation ofGSTT1, GSTM1 and SOD polymorphismin bladder cancer patients. Int Urol Nephrol. 2007;39(4):1043-8.
18. Terry PD, Umbach DM, Taylor JA. No association between SOD2 or NQO1 genotypes and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(3):753-4.
19. Manuguerra M, Matullo G, Veglia F, Autrup H, Dunning AM, Garte S, et al. Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions. Carcinogenesis. 2007;28(2):414-22.
20. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438.
21. Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D, et al. The manganese superoxide dismutase ala16val dimorphism modulates both mitochondrial import and MRNA stability. Pharmacogenet Genomics. 2005;15(5):311-9.
22. McCord JM. Superoxide dismutase in aging and disease: an overview. Methods Enzymol. 2002;349:331-41.